Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-2.92%
-2.08%
-3.34%
+9.79%
-19.01%
NVS
Novartis AG
$115.76
Chart
$110.39 (+4.86%)
$115.57 (+0.16%)
$100.03 (+15.73%)
$105.72 (+9.50%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.92%
-2.08%
-3.34%
+9.79%
-19.01%
NVS
Novartis AG
Current Price
$115.76
Login to view Novartis AG (NVS) recommendation from the last 90 days from financial news and social media.
Chart
$110.39 (+4.86%)
$115.57 (+0.16%)
$100.03 (+15.73%)
$105.72 (+9.50%)
NVS Latest Headlines
Global Smart Inhalers Market to Observe Impressive Growth at a CAGR of ~21% by 2032 | DelveInsight. Global Smart Inhalers Market to Observe Impressive Growth at a CAGR of ~21% by 2032 |. DelveInsightThe smart inhalers market is experiencing significant growth driven by the increasing incidence of respiratory diseases like asthma and COPD technological advancements widespread smartphone usage and a growing awareness of digital health solutions. These factors are expected to fuel strong demand
Thu May 29, 2025
Novartis announces commencement of tender offer to acquire Regulus Therapeutics.
Tue May 27, 2025
Are You Looking for a High-Growth Dividend Stock?. Dividends are one of the best benefits to being a shareholder but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Lets find out.
Wed May 21, 2025
Are You Looking for a High-Growth Dividend Stock?. Dividends are one of the best benefits to being a shareholder but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Lets find out.
Wed May 21, 2025
Novartis (NVS) Upgraded to Buy: What Does It Mean for the Stock?. Novartis (NVS) has been upgraded to a Zacks Rank #2 (Buy) reflecting growing optimism about the companys earnings prospects. This might drive the stock higher in the near term.
Thu May 15, 2025
Novartis (NVS) Upgraded to Buy: What Does It Mean for the Stock?. Novartis (NVS) has been upgraded to a Zacks Rank #2 (Buy) reflecting growing optimism about the companys earnings prospects. This might drive the stock higher in the near term.
Thu May 15, 2025
GSK To Buy Phase-3 Ready Liver Disease Drug For Up To $2 Billion. ) on Wednesday agreed to acquire .Under the agreement GSK will pay up to $2 billion in total cash consideration. This includes $1.2 billion upfront with the potential for additional success-based milestone payments totaling $800 million.GSK will also be responsible for success-based milestone payments and tiered royalties for efimosfermin owed to Novartis Pharma AG.Efimosfermin is a phase 3-ready investigational specialty medicine
Wed May 14, 2025
GSK To Buy Phase-3 Ready Liver Disease Drug For Up To $2 Billion. ) on Wednesday agreed to acquire .Under the agreement GSK will pay up to $2 billion in total cash consideration. This includes $1.2 billion upfront with the potential for additional success-based milestone payments totaling $800 million.GSK will also be responsible for success-based milestone payments and tiered royalties for efimosfermin owed to Novartis Pharma AG.Efimosfermin is a phase 3-ready investigational specialty medicine
Wed May 14, 2025
GSK To Buy Phase-3 Ready Liver Disease Drug For Up To $2 Billion. ) on Wednesday agreed to acquire .Under the agreement GSK will pay up to $2 billion in total cash consideration. This includes $1.2 billion upfront with the potential for additional success-based milestone payments totaling $800 million.GSK will also be responsible for success-based milestone payments and tiered royalties for efimosfermin owed to Novartis Pharma AG.Efimosfermin is a phase 3-ready investigational specialty medicine
Wed May 14, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
